- Home
- STRO vs NRXP Comparison
STRO vs NRXP Comparison
Compare STRO & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- NRXP
- Stock Information
- Founded
- STRO 2003
- NRXP 2015
- Country
- STRO United States
- NRXP United States
- Employees
- STRO N/A
- NRXP N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- NRXP Health Care
- Exchange
- STRO Nasdaq
- NRXP Nasdaq
- Market Cap
- STRO 68.1M
- NRXP 58.5M
- IPO Year
- STRO 2018
- NRXP N/A
- Fundamental
- Price
- STRO $0.88
- NRXP $3.04
- Analyst Decision
- STRO Hold
- NRXP Strong Buy
- Analyst Count
- STRO 7
- NRXP 5
- Target Price
- STRO $1.97
- NRXP $31.40
- AVG Volume (30 Days)
- STRO 980.5K
- NRXP 406.5K
- Earning Date
- STRO 11-12-2025
- NRXP 11-13-2025
- Dividend Yield
- STRO N/A
- NRXP N/A
- EPS Growth
- STRO N/A
- NRXP N/A
- EPS
- STRO N/A
- NRXP N/A
- Revenue
- STRO $104,473,000.00
- NRXP N/A
- Revenue This Year
- STRO $65.48
- NRXP N/A
- Revenue Next Year
- STRO N/A
- NRXP $395.09
- P/E Ratio
- STRO N/A
- NRXP N/A
- Revenue Growth
- STRO N/A
- NRXP N/A
- 52 Week Low
- STRO $0.52
- NRXP $1.10
- 52 Week High
- STRO $4.60
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- STRO 51.76
- NRXP 47.22
- Support Level
- STRO $0.77
- NRXP $2.95
- Resistance Level
- STRO $0.89
- NRXP $3.19
- Average True Range (ATR)
- STRO 0.07
- NRXP 0.25
- MACD
- STRO -0.00
- NRXP -0.05
- Stochastic Oscillator
- STRO 50.62
- NRXP 10.11
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.